Overview

Also Known As:MMTV-PyMT

Hemizygous MMTV-PyMT females develop palpable mammary tumors which metastasize to the lung. These mice have high penetrance of early onset of mammary cancer compared to other mammary tumor models. Male carriers also develop mammary tumors with a later age of onset. MMTV-PyVT transgenic mice express the Polyoma Virus middle T antigen under the direction of the mouse mammary tumor virus promoter/enhancer. This strain can be used as a platform to alter the tumor microenvironment.

Donating Investigator

Dr. William J. Muller, McGill University

Genetic overview

Genetic Background	Generation
001800 FVB/NJ	N18+N2 (2020-12-30 00:00:00)

Tg(MMTV-PyVT)634Mul

Allele Type
Transgenic (Inserted expressed sequence)

View Genetics

Research Applications

Cancer Research

View All Research Applications

Base Price

Starting at:

$255.00 Domestic price for female 4-week

333.51 Domestic price for breeder pair

View Price List

Details

Important Note

This strain is homozygous for the retinal degeneration allele Pde6b^rd1.

Detailed Description

The MMTV-PyVT transgene (MMTV-PyMT) includes the mouse mammary tumor virus (MMTV) long terminal repeat upstream of a cDNA sequence encoding the Polyoma Virus middle T antigen (PyVT). Transgenic mice are viable, but show loss of lactational ability coincident with transgene expression. Adenocarcinomas arise in virgin and breeder females as well as males. Tumors are multifocal, highly fibrotic, and involve the entire mammary fat pad. Males also develop adenocarcinoma of the seminal vesicles and hemangiomas. Female carriers develop palpable mammary tumors with a mean latency of 53 days of age, as compared with 92 days in B6.FVB-Tg(MMTV-PyVT)634Mul/LellJ mice (Stock No. 022974). Tumor-bearing females have 80-90% incidence of lung metastasis, a significant increase when compared to that found on the B6 congenic background. Transgene expression is detected at high levels in male and female mammary glands. Lower levels are detected in salivary gland, seminal vesicles, ovaries, and lungs (believed to be the result of pulmonary metastases) [Guy et al., 1992, Mol Cell Biol.].

This strain can be used as a platform to alter the tumor microenvironment. Tumor burden and pulmonary metastases have been shown to be reduced after in vivo TMP195 treatment by inducing the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumors. TMP195 treatment combined with chemotherapy regimens or T-cell checkpoint blockade in this model significantly enhances the durability of tumor reduction.

Of note, this transgene is also available on a congenic C57BL/6 genetic background as Stock No. 022974.

Development

To derive the MMTV-PyVT transgene (MMTV-PyMT), cDNA encoding the Polyoma Virus middle T antigen was inserted into the expression vector, pMMTV-SV40, resulting in a fusion gene of the PyVT oncogene and SV40 poly A and 3' processing signals, driven by the Mouse Mammary Tumor Virus (MMTV) LTR. Construct DNA was injected into the pronuclei of FVB/N zygotes. Transgenic progeny were identified by Southern blot analysis using a PyVT cDNA probe. Seven founder lines were established, and mice from founder line 634 were sent to The Jackson Laboratory. Upon arrival, sperm was cryopreserved. To establish our live colony, an aliquot of frozen sperm was used to fertilize FVB/NJ oocytes (Stock No. 001800).

Expression Data

Expressed Gene	PyVT, Polyoma virus middle T antigen, polyoma virus
Site of Expression

Control Suggestions

Noncarrier
001800 FVB/NJ

Additional Information

Considerations for Choosing Controls

Selected References

Guy CT; Cardiff RD; Muller WJ. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12(3):954-61PubMed: 1312220 MGI: J:46460

View All References

Genetics

Tg(MMTV-PyVT)634Mul

Allele Symbol: Tg(MMTV-PyVT)634Mul

Allele Name	transgene insertion 634, William Muller
Allele Type	Transgenic (Inserted expressed sequence)
Allele Synonym(s)	MMTV-PyMT; MMTV-PyVmT; MT634; MTAG; PyMT; PyV-mT; PyVT; Tg(MMTVPyVT)634Mul; TgN(MMTVPyVT)^634Mul; TgN(MMTVPyVT)634Mul
Gene Symbol and Name	Tg(MMTV-PyVT)634Mul, transgene insertion 634, William Muller
Gene Synonym(s)
Promoter	MMTV, Mouse Mammary Tumor Virus, MMTV
Expressed Gene	PyVT, Polyoma virus middle T antigen, polyoma virus
Strain of Origin	FVB/N
Chromosome	UN
General Note	Additional lines produced include lines 121, 196, 235, 654, 668, 670. These mice are used to study metastatic disease.
Molecular Note	This transgene expresses polyoma virus middle T antigen under the control of the mouse mammary tumor virus LTR. Expression of this transgene was detected at high levels in male and female mammary glands. Other expression sites include salivary gland, seminal vesicles, ovaries, and lung.
Mutations Made By	Dr. William Muller, McGill University

Disease/Phenotype

Disease Terms

Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.

breast cancer

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Cancer Research
- Increased Tumor Incidence
  - Mammary Gland Tumors
  - Gonadal Tumors
  - Other Tissues/Organs
- Other
  - tumor metastasis

Mammalian Phenotype Terms by Genotype

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Tg(MMTV-PyVT)634Mul/0
multiple strains

neoplasm

increased metastatic potential
- in F1 FVB/N mice crossed to the AKR/J strain, an increase in pulmonary metastatic index is seen

decreased metastatic potential
- in F1 FVB/N mice crossed to the RF/J, C58/J, C57BR/cdJ, NZB/B1NJ, I/LnJ, DBA/2J, KK/HiJ, MOLF/Ei, SEA/GnJ, NZW/LacJ, or CE/J strains, an decrease in pulmonary metastatic index is seen

decreased mammary gland tumor incidence
- inbred FVB/N strain
- in F1 FVB/N mice crossed to the P/J, DBA/1J, NZW/LacJ, C57BL/6NIcr, CAST/Ei, NOD/LtJ, CBA/CaJ, SWR/J, AKR/J, BUB/BnJ, ST/J, KK/HiJ, or MOLF/Ei strains, an increased latency of the onset of the appearance of primary mammary tumors is seen compared to the inbred FVB/N strain

increased mammary adenocarcinoma incidence
- in F1 FVB/N mice crossed to either the I/LnJ or C58/J strains, an acceleration of the onset of the appearance of primary mammary tumors is seen compared to the inbred FVB/N strain

endocrine/exocrine gland phenotype

decreased mammary gland tumor incidence
- inbred FVB/N strain
- in F1 FVB/N mice crossed to the P/J, DBA/1J, NZW/LacJ, C57BL/6NIcr, CAST/Ei, NOD/LtJ, CBA/CaJ, SWR/J, AKR/J, BUB/BnJ, ST/J, KK/HiJ, or MOLF/Ei strains, an increased latency of the onset of the appearance of primary mammary tumors is seen compared to the inbred FVB/N strain

increased mammary adenocarcinoma incidence
- in F1 FVB/N mice crossed to either the I/LnJ or C58/J strains, an acceleration of the onset of the appearance of primary mammary tumors is seen compared to the inbred FVB/N strain

integument phenotype

increased mammary adenocarcinoma incidence
- in F1 FVB/N mice crossed to either the I/LnJ or C58/J strains, an acceleration of the onset of the appearance of primary mammary tumors is seen compared to the inbred FVB/N strain

decreased mammary gland tumor incidence
- inbred FVB/N strain
- in F1 FVB/N mice crossed to the P/J, DBA/1J, NZW/LacJ, C57BL/6NIcr, CAST/Ei, NOD/LtJ, CBA/CaJ, SWR/J, AKR/J, BUB/BnJ, ST/J, KK/HiJ, or MOLF/Ei strains, an increased latency of the onset of the appearance of primary mammary tumors is seen compared to the inbred FVB/N strain

Genotype: Tg(MMTV-PyVT)634Mul/0
involves: C57BL/6 * FVB/N

endocrine/exocrine gland phenotype

increased mammary gland tumor incidence
- mice develop mammary gland tumors with a median age of tumor latency of 73 days in females and 137 days in males unlike wild-type mice

growth/size/body region phenotype

increased lung weight

integument phenotype

increased mammary gland tumor incidence
- mice develop mammary gland tumors with a median age of tumor latency of 73 days in females and 137 days in males unlike wild-type mice

neoplasm

increased mammary gland tumor incidence
- mice develop mammary gland tumors with a median age of tumor latency of 73 days in females and 137 days in males unlike wild-type mice

respiratory system phenotype

increased lung weight

Genotype: Tg(MMTV-PyVT)634Mul/0
involves: 129 * C57BL/6 * FVB/N

endocrine/exocrine gland phenotype

increased mammary adenocarcinoma incidence
- all female virgin mice develop cancer tumors in the breast by 14 weeks of age

integument phenotype

increased mammary adenocarcinoma incidence
- all female virgin mice develop cancer tumors in the breast by 14 weeks of age

neoplasm

increased mammary adenocarcinoma incidence
- all female virgin mice develop cancer tumors in the breast by 14 weeks of age

The following phenotype relates to a compound genotype created using this strain

Genotype: Tg(MMTV-PyVT)634Mul/0
FVB/N-Tg(MMTV-PyVT)634Mul/J

endocrine/exocrine gland phenotype

increased mammary gland tumor incidence
- mice develop mammary gland tumors with a median age of tumor latency of 66 days in females and 133.5 days in males unlike wild-type mice

respiratory system phenotype

increased lung weight

growth/size/body region phenotype

increased lung weight

integument phenotype

increased mammary gland tumor incidence
- mice develop mammary gland tumors with a median age of tumor latency of 66 days in females and 133.5 days in males unlike wild-type mice

neoplasm

increased tumor growth/size
- proliferation and apoptosis of tumor cells are increased compared with cells from Mmp9^tm1Tvu/Mmp9^tm1Tvu Tg(MMTV-PyVT)634Mul mice with the balance resulting in increased tumor size

abnormal tumor morphology
- metastatic lung tumors exhibit more blood vessel staining compared with equivalent tumors in Mmp9^tm1Tvu/Mmp9^tm1Tvu Tg(MMTV-PyVT)634Mul mice

increased mammary gland tumor incidence
- mice develop mammary gland tumors with a median age of tumor latency of 66 days in females and 133.5 days in males unlike wild-type mice

Genotype: Tg(MMTV-PyVT)634Mul/0
FVB/N-Tg(MMTV-PyVT)634Mul/Nci

neoplasm

increased metastatic potential
- pulmonary metastases are observed in 94% of tumor-bearing female mice and 80% of tumor-bearing male mice

increased mammary adenocarcinoma incidence
- mammary tumors appear in males and females with 100% penetrance by 40 days of age
- tumors are multifocal, highly fibrotic, and involved the entire mammary fat pad
- all female carriers develop palpable mammary tumors by 5 weeks of age; male carriers also develop these tumors with a later age of onset (median 83 days of age)

endocrine/exocrine gland phenotype

increased mammary adenocarcinoma incidence
- tumors are multifocal, highly fibrotic, and involved the entire mammary fat pad
- mammary tumors appear in males and females with 100% penetrance by 40 days of age
- all female carriers develop palpable mammary tumors by 5 weeks of age; male carriers also develop these tumors with a later age of onset (median 83 days of age)

lactation failure
- inability to lactate from the time of the first pregnancy

integument phenotype

increased mammary adenocarcinoma incidence
- all female carriers develop palpable mammary tumors by 5 weeks of age; male carriers also develop these tumors with a later age of onset (median 83 days of age)
- tumors are multifocal, highly fibrotic, and involved the entire mammary fat pad
- mammary tumors appear in males and females with 100% penetrance by 40 days of age

lactation failure
- inability to lactate from the time of the first pregnancy

Genotype: Tg(MMTV-PyVT)634Mul/0
involves: FVB/N

integument phenotype

increased mammary gland tumor incidence
- extensive adenomas are found
- tumor nodules are present throughout the entire mammary gland
- average onset of tumor development is 66 days
- tumors exhibit more linear, thicker collagen fibers consistent with aggressive and invasive tumors
- primary tumors are highly fibrotic
- tumors have higher CD31 staining, indicating increased primary tumor vasculature

abnormal mammary gland morphology
- tumor nodules are present throughout the entire mammary gland

neoplasm

increased mammary gland tumor incidence
- tumors have higher CD31 staining, indicating increased primary tumor vasculature
- tumor nodules are present throughout the entire mammary gland
- tumors exhibit more linear, thicker collagen fibers consistent with aggressive and invasive tumors
- average onset of tumor development is 66 days
- extensive adenomas are found
- primary tumors are highly fibrotic

endocrine/exocrine gland phenotype

increased mammary gland tumor incidence
- tumors have higher CD31 staining, indicating increased primary tumor vasculature
- primary tumors are highly fibrotic
- tumor nodules are present throughout the entire mammary gland
- extensive adenomas are found
- tumors exhibit more linear, thicker collagen fibers consistent with aggressive and invasive tumors
- average onset of tumor development is 66 days

abnormal mammary gland morphology
- tumor nodules are present throughout the entire mammary gland

Phenotype Information

References

Guy CT; Cardiff RD; Muller WJ. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12(3):954-61PubMed: 1312220 MGI: J:46460

Additional References

Dorward AM; Fancher KS; Duffy TM; Beamer WG; Walt H. 2005. Early neoplastic and metastatic mammary tumours of transgenic mice detected by 5-aminolevulinic acid-stimulated protoporphyrin IX accumulation. Br J Cancer 93(10):1137-43PubMed: 16251872 MGI: J:102838
Guerriero JL; Sotayo A; Ponichtera HE; Castrillon JA; Pourzia AL; Schad S; Johnson SF; Carrasco RD; Lazo S; Bronson RT; Davis SP; Lobera M; Nolan MA; Letai A. 2017. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature 543(7645):428-432PubMed: 28273064 MGI: J:244490
Le Voyer T; Rouse J; Lu Z; Lifsted T; Williams M; Hunter KW. 2001. Three loci modify growth of a transgene-induced mammary tumor: suppression of proliferation associated with decreased microvessel density. Genomics 74(3):253-61PubMed: 11414753 MGI: J:70229
Muraoka RS; Dumont N; Ritter CA; Dugger TC; Brantley DM; Chen J; Easterly E; Roebuck LR; Ryan S; Gotwals PJ; Koteliansky V; Arteaga CL. 2002. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109(12):1551-9PubMed: 12070302 MGI: J:86709
Politi K; Kljuic A; Szabolcs M; Fisher P; Ludwig T; Efstratiadis A. 2004. 'Designer' tumors in mice. Oncogene 23(8):1558-65PubMed: 14661057 MGI: J:87544
Saez E; Rosenfeld J; Livolsi A; Olson P; Lombardo E; Nelson M; Banayo E; Cardiff RD; Izpisua-Belmonte JC; Evans RM. 2004. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev 18(5):528-40PubMed: 15037548 MGI: J:89019

Additional - Tg(MMTV-PyVT)634Mul related

Technical Support

CONTACT TECHNICAL SUPPORT

Genotyping Protocols
- Standard PCR:Tg(MMTV-PyVT)634Mul
- Standard PCR:Tg(MMTV-PyVT)634Mul
- Probe:Tg(MMTV-PyVT)634Mul Probe
- Genotyping resources and troubleshooting
Dietary Information
- LabDiet® 5K52 formulation (6% fat)
Breeding Considerations

When maintaining a live colony, FVB/NJ inbred females (Stock No. 001800) may be bred with hemizygous males. The expected coat color from breeding is Albino.
- Additional Breeding and Husbandry Support
Mating System
- Noncarrier x Hemizygote
Appearance
- albino
  Related Genotype: Tyr^c/Tyr^c
Citation
When using the MMTV-PyMT mouse strain in a publication, please cite the originating article(s) and include JAX stock #002374 in your Materials and Methods section.

Animal Health Reports

Facility Barrier Level Descriptions

AX11 (Maximum)

Pricing & Availability

Available

Domestic
International

Live Mouse

Age

Genotype

Price

weeks

Breeder Pair

Sex

Genotype

Price

Female
Male

Cryorecovery - Pricing

Service/Product	Description	Price
> >	Hemizygous or Non carrier for Tg(MMTV-PyVT)634Mul

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.

Terms Of Use

General Terms and Conditions

Questions about Terms of Use

Additional Use Restrictions Apply

Use of MICE by companies or for-profit entities requires a license prior to shipping.

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

Also Known As:MMTV-PyMT

Donating Investigator

Genetic overview

Research Applications

Base Price

Important Note

Detailed Description

Development

Expression Data

Control Suggestions

Additional Information

Selected References

Tg(MMTV-PyVT)634Mul

Allele Symbol: Tg(MMTV-PyVT)634Mul

Disease Terms

Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Mammalian Phenotype Terms by Genotype

Genotype: Tg(MMTV-PyVT)634Mul/0multiple strains

neoplasm

endocrine/exocrine gland phenotype

integument phenotype

Genotype: Tg(MMTV-PyVT)634Mul/0involves: C57BL/6 * FVB/N

endocrine/exocrine gland phenotype

growth/size/body region phenotype

integument phenotype

neoplasm

respiratory system phenotype

Genotype: Tg(MMTV-PyVT)634Mul/0involves: 129 * C57BL/6 * FVB/N

endocrine/exocrine gland phenotype

integument phenotype

neoplasm

Genotype: Tg(MMTV-PyVT)634Mul/0FVB/N-Tg(MMTV-PyVT)634Mul/J

endocrine/exocrine gland phenotype

respiratory system phenotype

growth/size/body region phenotype

integument phenotype

neoplasm

Genotype: Tg(MMTV-PyVT)634Mul/0FVB/N-Tg(MMTV-PyVT)634Mul/Nci

neoplasm

endocrine/exocrine gland phenotype

integument phenotype

Genotype: Tg(MMTV-PyVT)634Mul/0involves: FVB/N

integument phenotype

neoplasm

endocrine/exocrine gland phenotype

Phenotype Information

References

Additional References

Additional - Tg(MMTV-PyVT)634Mul related

Genotyping Protocols

Dietary Information

Breeding Considerations

Mating System

Appearance

Citation

Animal Health Reports

Live Mouse

Breeder Pair

Cryorecovery - Pricing

Payment Terms and Conditions

The Jackson Laboratory's Genotype Promise

Terms Of Use

Additional Use Restrictions Apply

Licensing Information

Genotype: Tg(MMTV-PyVT)634Mul/0
multiple strains

Genotype: Tg(MMTV-PyVT)634Mul/0
involves: C57BL/6 * FVB/N

Genotype: Tg(MMTV-PyVT)634Mul/0
involves: 129 * C57BL/6 * FVB/N

Genotype: Tg(MMTV-PyVT)634Mul/0
FVB/N-Tg(MMTV-PyVT)634Mul/J

Genotype: Tg(MMTV-PyVT)634Mul/0
FVB/N-Tg(MMTV-PyVT)634Mul/Nci

Genotype: Tg(MMTV-PyVT)634Mul/0
involves: FVB/N